BRIDGEWATER, N.J., April 10, 2019 /PRNewswire/ -- Starting in June,
Sanofi will further expand its innovative Insulins
Valyou Savings Program so people living with diabetes
in the United States can pay
$99 to access their Sanofi insulins*
with a valid prescription, for up to 10 boxes of pens and/or 10 mL
vials per month. The expansion of this program helps to address the
challenge too many patients face regarding unpredictable and
unaffordable pricing for their insulin.
"It is unacceptable to Sanofi
that some people living with diabetes are struggling to pay for
their insulin, so we have moved to act creatively and aggressively
to help address affordability and access needs," said
Michelle Carnahan, Head of North
America Primary Care at Sanofi. "By giving those who require
both long-acting and/or mealtime insulins or use more than one box
of pens or one vial per month access to their insulins for one flat
price, we aim to help limit the burden on the individuals who have
high out-of-pocket costs at the pharmacy counter."
People exposed to high out-of-pocket prices at the pharmacy
counter can participate in the Insulins Valyou
Savings Program regardless of income level. This includes those who
are paying high retail prices for their insulin and those who don't
qualify for other patient assistance programs.
Under current government regulations, pharmaceutical companies
cannot offer this type of program to patients insured under
Medicare, Medicaid, or similar federal or state programs, though
Sanofi supports changing rules to expand this access program to all
those who might benefit.
Kelly L.
Close, co-founder, The diaTribe Foundation, and president,
Close Concerns, said, "Sanofi is taking this vital,
transformational action to make its insulins more affordable
through this program. The U.S. diabetes community is in the middle
of a crisis, because our dysfunctional healthcare system doesn't
allow equal, affordable, access to insulin. As patient advocates at
diaTribe, we have been strongly urging manufacturers, insurers,
healthcare providers, pharmacy benefit managers – and the
government – to work together to help alleviate this problem.
Today, we recognize Sanofi for their outstanding leadership in
order to make their insulins available at a better price for all,
regardless of income or dosing needs."
A year ago, Sanofi launched the Insulins Valyou Savings Program
to enable those who pay cash to pay the set prices of $99 for one 10mL vial or $149 for a box of pens. Now, up to 10 boxes of
pens and/or 10mL vials will cost $99
per month.
Since it was launched last April, the program has resulted in
approximately $10 million in patient
savings. The program is available at U.S. pharmacies.
"As premiums on insurance plans
continue to climb, some people living with diabetes have had to
exit the higher premiums so they can find ways to pay less. The
result may be the loss of prescription benefits," said
Lon Chenowith, who has been living
with diabetes for more than 30 years. "That was what I was
forced to do last year. Sanofi has savings programs for
people who have been prescribed their insulin that
can help them save on prescription costs. They have been
a big encouragement to people like
me."
For more information or to learn how to access this program,
visit www.InsulinsValYOU.com.
Additional patient resources available for accessing Sanofi
medicines
Sanofi continues to offer other resources to make insulins more
accessible including co-pay cards which may limit out-of-pocket
expenses sometimes to $0 for all
commercially insured patients regardless of income level. In
addition, Sanofi offers assistance programs that provide
medications, including insulin, at no charge for qualified
low-income, uninsured patients through the patient assistance
component of the Sanofi Patient Connection program. Together,
these programs demonstrate the company's dedication to finding
support to help people living with diabetes gain access to the
insulins they need.
Sanofi also encourages anyone who is prescribed a Sanofi
medicine who may be having financial challenges or trouble
navigating their insurance, to call Sanofi Patient Connection at
(888) 847-4877 where eligible patients can be connected to the
medicines and resources they need at no cost.
* The Insulins Valyou Savings Program
does not include Sanofi's combination insulin product.
About Sanofi
Sanofi is dedicated to supporting people through their health
challenges. We are a global biopharmaceutical company focused on
human health. We prevent illness with vaccines, provide innovative
treatments to fight pain and ease suffering. We stand by the few
who suffer from rare diseases and the millions with long-term
chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is
transforming scientific innovation into healthcare solutions around
the globe.
Sanofi, Empowering Life
Media Relations
Contact
|
Investor Relations
Contact
|
Ashleigh
Koss
|
George
Grofik
|
Tel.: +1 908 981
8745
|
Tel.: +33 (0)1 53 77
45 45
|
Ashleigh.Koss@sanofi.com
|
ir@sanofi.com
|
Sanofi Forward-Looking Statements
This press
release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial
results, events, operations, services, product development and
potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words
"expects", "anticipates", "believes", "intends", "estimates",
"plans" and similar expressions. Although Sanofi's management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, the uncertainties inherent in research and development,
future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the absence of guarantee that the
product candidates if approved will be commercially successful, the
future approval and commercial success of therapeutic alternatives,
Sanofi's ability to benefit from external growth opportunities, to
complete related transactions and/or obtain regulatory clearances,
risks associated with intellectual property and any related pending
or future litigation and the ultimate outcome of such
litigation, trends in exchange rates and prevailing interest
rates, volatile economic conditions, the impact of cost containment
initiatives and subsequent changes thereto, the average number of
shares outstanding as well as those discussed or identified in the
public filings with the SEC and the AMF made by Sanofi, including
those listed under "Risk Factors" and "Cautionary Statement
Regarding Forward-Looking Statements" in Sanofi's annual report on
Form 20-F for the year ended December 31,
2018. Other than as required by applicable law, Sanofi does
not undertake any obligation to update or revise any
forward-looking information or statements.
Source: Sanofi (EURONEXT: SAN) (NASDAQ: SNY)
View original content to download
multimedia:http://www.prnewswire.com/news-releases/sanofi-provides-unprecedented-access-to-its-insulins-for-one-set-monthly-price-300828431.html
SOURCE Sanofi